ACR Convergence 2026

November 6-11, 2026. Orlando, Florida.

View by Number View by Title View Sessions

All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 2216

Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I CARLYSLE Study
Abstract Number: 1804

Obese Dynapenia vs Sarcopenic Obesity: Distinct Muscle-Adiposity Phenotypes Associated with Disease Activity and Functional Disability in Rheumatoid Arthritis
Abstract Number: 1009

Obesity and Racial Variation in Immune Cell Populations and Clinical Features of Systemic Lupus Erythematosus
Abstract Number: 0323

Obesity and the Initiation of Chronic Opioid Use in Patients with Systemic Lupus Erythematosus: A Longitudinal Cohort Study with Time-Varying Sensitivity Analysis[
Abstract Number: 0324

Obesity as an Emerging Comorbidity at Death Among Individuals With Systemic Lupus Erythematosus: A Nationwide Analysis, 1999-2020
Abstract Number: 2338

Obesity, Disease Type, and Advanced Therapy Utilization Across Spondyloarthritis Subtypes: A Retrospective Study
Abstract Number: 1882

Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients With IgG4-Related Disease: Results From the Phase 3 Randomized, Placebo-Controlled Indigo Trial
Abstract Number: 0273

Obinutuzumab Achieves Sustained Glucocorticoid Control: An Exploratory Analysis From a Phase III Trial in Active Systemic Lupus Erythematosus
Abstract Number: 1232

Obinutuzumab Facilitates Tubular Repair in Lupus Nephritis Independently of Histologic or Clinical Response: Post Hoc Analyses of Urine EGF in a Phase III Trial
Abstract Number: 0222

Obinutuzumab in Systemic sclerosis: a multicentre retrospective case series
Abstract Number: 1823

Obinutuzumab Induces Histologic Remission and Deep Kidney Parenchymal B-cell Depletion in Patients With Lupus Nephritis: Exploratory Analyses From a Phase III Trial
Abstract Number: 2217

Obinutuzumab Induces Rapid and Durable Resolution of Clinical Disease Activity Across Active Clinical SLEDAI-2K Organ Domains in Patients With Systemic Lupus Erythematosus
Abstract Number: 1233

Obinutuzumab Reduces Fatigue and Improves Health-Related Quality of Life: Results from a Phase III Trial in Systemic Lupus Erythematosus
Abstract Number: 0524

Objective Device-Based Assessment of Psychomotor Slowing in Inpatients with Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 0460

Ocadusertib, a Novel Oral Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor, Demonstrates Target Engagement but Limited Clinical Efficacy in Moderately-to-Severely Active Rheumatoid Arthritis: Results from a Phase 2a Trial
Abstract Number: 0819

Occurrence and accrual of organ damage in Systemic Lupus Erythematosus patients using the French national claims database: results from the EPILOG study
Abstract Number: 1078

Off-Label Use of Anifrolumab in Dermatomyositis: Early Treatment Patterns in a Global Real-World Cohort
Abstract Number: 1024

Off-the-shelf Anti-CD19 CAR T-cell Therapy Efficacy Reveals Biomarker Candidates for Fatigue in SLE
Abstract Number: 1234

Off-the-Shelf CD19 CAR T-cell Therapy Demonstrates Feasibility of Outpatient Administration, Expanding Access to Community-Based Care
Abstract Number: 2339

One-Year and Three-Year Comparative Outcomes Among Patients With Psoriasis Treated With Bimekizumab Versus Secukinumab: A Propensity Score-Matched Real-World Study
Abstract Number: 2115

One-Year Real-World Evidence on Treatment Persistence and Glucocorticoid-Sparing Effects of Upadacitinib in a Prospective Giant Cell Arteritis Cohort
Abstract Number: 1756

Ongoing Hydroxychloroquine Use in Rheumatic Diseases is not associated with risk of COVID-19 infection, COVID-19 hospitalization, or post-COVID-19 mortality: A National Integrated Health System Study
Abstract Number: 1415

Ongoing Hydroxychloroquine use is associated with reduced all-cause mortality in rheumatoid arthritis and systemic lupus erythematosus, but not in osteoarthritis: A National Veterans Administration (VA) database study
Abstract Number: 1554

Ontario Rheumatologists’ Attitudes Toward the Management of Fibromyalgia: A 2012-2026 Comparison Study
Abstract Number: 0849

Operational Advancements in a Large Academic Rheumatology Practice
Abstract Number: 2543

Opioid Prescribing Practices Among U.S. Academic Rheumatologists: A National Observational Study
Abstract Number: 1788

Opioid Use in Systemic Lupus Erythematosus: A Real-World Analysis of Prevalence and Subgroup Differences
Abstract Number: 2559

Opportunistic CT-derived Hounsfield units are associated with vertebral fractures in chronic haemodialysis
Abstract Number: 1683

Opportunistic Infection Signal in Rheumatic Disease Patients by Biologic Class
Abstract Number: 1939

Opposing Pathogenic Roles of Endothelial and Fibroblast Insulin-Like Growth Factor Binding Protein-7 (IGFBP7) in Systemic Sclerosis-associated Pulmonary Hypertension (SSc-PH)
Abstract Number: 1352

Optimal strategy for Cardiovascular risk assessment in Spondyloarthritis: A comparative analysis between traditional cardiovascular risk score (QRISK3 score) versus traditional risk score supplemented with either Carotid ultrasound or Coronary CT angiography
Abstract Number: 0616

Optimal Tender-Swollen Joint Difference Thresholds to Identify Fibromyalgia in Adults with Rheumatoid Arthritis
Abstract Number: 1598

Optimizing Positivity Thresholds for Non-Jo-1 Anti-tRNA Synthetase Line Immunoassay in Antisynthetase Syndrome: A Multi-Centre Diagnostic Performance Study
Abstract Number: 0393

Optimizing the Use of Patient-Reported Outcome Measures in Axial Spondyloarthritis: A Mixed-Methods Study from the QUESTIONAX Project.
Abstract Number: 1388

Oral Disease Burden and Risk of Systemic Infection and Sepsis in Adults with Sjögren’s Disease: An Insurance Claims-Based Analysis
Abstract Number: 2405

Oral Glucocorticoid Use and Discontinuation Among JAK inhibitors and Biologic DMARDs in Rheumatoid Arthritis: A Canadian Retrospective Cohort Study
Abstract Number: 0795

Oral Health in Patients with Rheumatic Diseases: Outcomes from an Interdisciplinary Dental-Rheumatology Clinic
Abstract Number: 1072

Oral Microbiome Signatures Associated with Patient-Reported Recovery After Total Knee Arthroplasty
Abstract Number: 1416

Oral Split-Dose vs. Subcutaneous Methotrexate in Active Rheumatoid Arthritis (SCOOT study): A Multicentric Randomized Controlled Trial
Abstract Number: 0936

Organ Damage and Its Predictors in Primary Antiphospholipid Syndrome Classified by the 2023 ACR/EULAR Criteria: A Single-Center Brazilian Cohort
Abstract Number: 1276

Organ Damage and Its Relationship with Disease Activity in Systemic Lupus Erythematosus: Insights from the Lupus Federated Data Network (LupusNet)
Abstract Number: 0689

Organ Damage in IgG4-Related Disease is Common at the Time of Initial Evaluation and is Driven by Disease Duration
Abstract Number: 1518

Organ involvement patterns by anti Scl 70 and anti centromere status in juvenile systemic sclerosis. Results of the juvenile scleroderma inception cohort.
Abstract Number: 0581

Organ Screening Practices in Juvenile Systemic Sclerosis: Baseline and Longitudinal Data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Identifying Juvenile Scleroderma Immunophenotype Subsets (SCORE) Cohort
Abstract Number: 1277

Organ-Specific Treatment Response: Real-World Mucocutaneous and Musculoskeletal Outcomes After 6 and 12 Months of Anifrolumab Treatment
Abstract Number: 2757

Osteoarthritis Burden in Michigan Compared with the U.S. Midwest: Trends in Age-Standardized Prevalence and Disability
Abstract Number: 2758

Osteoporosis in Indian Patients with Rheumatoid Arthritis: A Multicenter Prospective Cross-Sectional Study of Prevalence, Risk Factors, and 10-Year Fracture Probability Using the Indian FRAX® Tool
Abstract Number: 0627

Osteoporosis Matters: Impact of Anti-osteoporotic Treatment on Mortality following Osteoporotic Hip Fracture
Abstract Number: 1566

Osteoporotic Fracture Risk with Glucocorticoid-Sparing Therapies in Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 2089

OTX-201: A Novel Off-the-Shelf In Vivo Anti-CD19 CAR T Platform Designed to Improve Safety and Access to Immune Reset in Autoimmune Diseases
Abstract Number: 2116

Outcomes Associated with Major Organ Involvement, Biologic Therapy, and Anticoagulant Use in Behçet’s Syndrome: A Propensity Score-Matched Multicenter Study
Abstract Number: 2788

Outcomes of Direct Subcutaneous Remsima (Infliximab) Initiation Without a Loading Dose Compared With Conventional Induction Regimens in Chronic Inflammatory Rheumatic Diseases
Abstract Number: 2679

Outcomes of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Rheumatoid arthritis: A Systematic Review and Meta-analysis
Abstract Number: 0325

Outcomes of Pulmonary Arterial Hypertension in SLE: A propensity-matched national cohort study excluding Systemic Sclerosis
Abstract Number: 1235

Outcomes of Pure Membranous Lupus Nephritis at a South Indian Tertiary Referral center: A Retrospective Cohort Study
Abstract Number: 0498

Outcomes of Rheumatoid Arthritis with Pulmonary Involvement: A National Inpatient Sample Analysis (2016-2021)
Abstract Number: 0896

Outpatient SARS-CoV-2 infection is not associated with excess lung damage in rheumatoid arthritis in the Omicron era: A prospective study with pre-pandemic controls
Abstract Number: 2938

Overall, Immune-Mediated, and Hematologic Safety Outcomes Following Fludarabine/Cyclophosphamide Lymphodepletion and NKX019, an Allogeneic CD19-Targeted CAR NK-Cell Therapy, in B-Cell-Mediated Autoimmune Diseases
Abstract Number: 1057

Overexpression of the Human Paraoxonase-1 Transgene Associates with an Altered Gut Fecal Microbiome, Lower LPS Levels, and Reduced Disease Activity in K/BxN Serum Transfer-Induced Arthritis
Abstract Number: 1709

Overlooked Disparities in Musculoskeletal Care: Perceived Discrimination by Age, Sexuality, and Medically Underserved Status
Abstract Number: 0099

Oxylipin and Fatty Acid Signatures Linked to Reduced Biologic Response in Obese Rheumatoid Arthritis Patients: A CorEvitas Cohort Study

All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z